Download Files:
Trelagliptin (succinate)
$50 – $160
Products Details
Product Description
– Trelagliptin (SYR-472) succinate is a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM)[1].
Web ID
– HY-15408A
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture)
Shipping
– Room Temperature
Applications
– Metabolism-protein/nucleotide metabolism
Molecular Formula
– C22H26FN5O6
References
– [1]Bhumika D Patel, et al. Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors. Eur J Med Chem. 2014 Mar 3;74:574-605.|[2]Charles E Grimshaw, et al. Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism. PLoS One. 2016 Jun 21;11(6):e0157509.|[3]Shiliang Li, et al. Discovery of a Natural-Product-Derived Preclinical Candidate for Once-Weekly Treatment of Type 2 Diabetes. J Med Chem. 2019 Mar 14;62(5):2348-2361.
CAS Number
– 1029877-94-8
Molecular Weight
– 475.47
Compound Purity
– 99.96
SMILES
– O=C(C=C(N1C[C@H](N)CCC1)N2CC3=C(C#N)C=CC(F)=C3)N(C)C2=O.O=C(O)CCC(O)=O
Clinical Information
– Launched
Research Area
– Metabolic Disease
Solubility
– DMSO : ≥ 50 mg/mL|H2O : 100 mg/mL (ultrasonic)
Target
– Dipeptidyl Peptidase
Isoform
– DPP-4
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
